

PTO-1449 (Modified) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 012441.00013	SERIAL NUMBER TBA
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT Glenn J. Dorin	
		FILING DATE November 30, 2001	GROUP ART UNIT TBA

PTO-1449
516588
516589
100096169
100096169
100096169
100096169

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE
LM	5,212,091	5/18/93	Diaz-Collier et al.	435	69.6	
LM	5,466,893	11/14/95	Wu et al. NAKATAKI	174	261	

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION YESTD
	0 473 564 A1	3/1/92	Europe			
	0 539 632 A2	9/8/93	Europe			
	0 325 891	8/1/89	Europe			
	0 131 864	1/23/85	Europe			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Rainer Rudolph "Successful Protein Folding on a Industrial Scale" Protein Engineering: Principles and Practice, Chapter 10, pages 283-298 -1996
Rudolph & Lillie "In vitro folding of inclusion body proteins" Folding of Acidic Fibroblast Growth Factor, FASEB J. 10, pgs. 49-56
Daborn et al. "Effect of Polyanions on the Refolding of Human Acidic Fibroblast Growth Factor" The Journal of Biological Chemistry, Vol. 266, No. 35, December 15, 1991, pages 23637-23640
Bernhard Fischer et al. "Isolation, Renaturation, and Formation of Disulfide Bonds of Eukaryotic Proteins Expressed in Escherichia coli as Inclusion Bodies" Biotechnology and Bioengineering, Vol. 41, pages 3-13, (1993)
J. Harenberg et al. "Tissue factor pathway inhibitor: proposed heparin recognition region" Blood Coagulation and Fibrinolysis, Vol. 6, Suppl. 1, 1995
Mark E. Gustafson et al. "Renaturation and Purification of Human Tissue Factor Pathway Inhibitor Expressed in Recombinant E. coli" Protein Expression and Purification 5, 233-241 (1994)

EXAMINER	RITA MITRA	DATE CONSIDERED	8/1/04
----------	------------	-----------------	--------

EXAMINER: Initial citation if reference was considered. Draw line through citation if not in conformance to MPEP 609 and not considered. Include copy of this form with next communication to applicant.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for Form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

Application Number	TBA
Filing Date	November 30, 2001
First Named Inventor	Glenn J. Dorin
Group Art Unit	TBA
Examiner Name	TBA
Attorney Docket Number	012441.00013

Sheet 2 of 2

Attorney Docket Number 012441.00013

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

**Examiner
Signature**

RITA MITRA

**Date
Considered**

8/1/04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04.

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.